Featured Research

from universities, journals, and other organizations

Medication Reduces Risk Of Heart Attack And Cardiovascular Death Before And After Angioplasty

Date:
September 4, 2005
Source:
JAMA and Archives Journals
Summary:
Use of the antiplatelet drug clopidogrel before a coronary angioplasty reduced the risk of cardiovascular death, heart attack or stroke within 30 days following the procedure, according to an article in the September 14 issue of JAMA.

Use of the antiplatelet drug clopidogrel before a coronary angioplastyreduced the risk of cardiovascular death, heart attack or stroke within30 days following the procedure, according to an article in theSeptember 14 issue of JAMA.

Dual antiplatelet therapy following percutaneous coronary intervention(PCI; procedures such as angioplasty in which a catheter-guided balloonis used to open a narrowed coronary artery, often accompanied byplacement of a stent in the artery), using a combination of a drugssuch as ticlopidine or clopidogrel along with aspirin, helps reduceplatelet activation and thrombotic and ischemic complications,according to background information in the article. However, theoptimal timing of the initiation of clopidogrel has been debated. Thebenefit of clopidogrel pretreatment started hours to days before PCIcompared with treatment given at the time of PCI in high-risk patientswith acute coronary syndromes remains incompletely defined, and currentguidelines do not universally recommend pretreatment.

Marc S. Sabatine, M.D., M.P.H., of Brigham and Women's Hospitaland Harvard Medical School, Boston, and colleagues conducted a study todetermine if clopidogrel pretreatment hours to days before PCI issuperior to clopidogrel treatment initiated at the time of PCI inpreventing major adverse cardiovascular events in patients undergoingPCI after initial pharmacological therapy for ST-segment elevationmyocardial infarction (STEMI; a severe heart attack with specific typeof findings on an electrocardiogram).

The PCI-Clopidogrel as Adjunctive Reperfusion Therapy(CLARITY) study included an analysis of 1,863 patients undergoing PCIafter mandated angiography in CLARITY-Thrombolysis in MyocardialInfarction (TIMI) 28, a randomized, double-blind, clinical trial ofclopidogrel vs. placebo in patients receiving fibrinolytics (medicationfor dissolving blood clots) for STEMI. Patients were enrolled at 319sites in 23 countries from February 2003 through October 2004. Patientsreceived aspirin and were randomized to receive either clopidogrel (300mg loading dose [a comparatively large dose given at the beginning oftreatment to start getting the effect of a drug more quickly], then 75mg once daily) or placebo initiated with fibrinolysis and given untilcoronary angiography, which was performed 2 to 8 days after initiationof the study drug. For patients undergoing coronary artery stenting, itwas recommended that open-label clopidogrel (including a loading dose)be administered after the diagnostic angiogram. Thus, for patients whoultimately underwent PCI, the study medication (clopidogrel or placebo)that patients were randomized to when they first presented to thehospital became the pretreatment before their PCI.

The researchers found that pretreatment with clopidogrelsignificantly reduced by 46 percent the odds of cardiovascular death,heart attack, or stroke following PCI (34 events [3.6 percent] vs. 58events [6.2 percent]. Pretreatment with clopidogrel also reduced theodds by 38 percent of heart attack or stroke prior to PCI (37 [4.0percent] vs. 58 [6.2 percent]. Overall, pretreatment with clopidogrelresulted in a 41 percent reduction in the odds of cardiovascular death,heart attack, or stroke from randomization through 30 days (70 [7.5percent] vs. 112 [12.0 percent].There was no significant excess in therates of TIMI major or minor bleeding (18 [2.0 percent] vs. 17 [1.9percent].

"In terms of implications of PCI-CLARITY for clinical practice,for every 100 patients undergoing PCI in whom a strategy of clopidogrelpretreatment is adopted, approximately 2 myocardial infarctions [MIs;heart attacks] would be prevented before PCI and an additional 2cardiovascular deaths, MIs, or strokes would be prevented after PCI to30 days. Overall, only 23 patients would need to be pretreated withclopidogrel to prevent 1 cardiovascular death, MI, or stroke. Thisbenefit with pretreatment is achieved when compared with the currentpractice in which patients receive a loading dose of clopidogrel at thetime of PCI and a maintenance dose thereafter. Thus in 100 patients, 4major cardiovascular events can be avoided simply by the use of 1 to 3doses of clopidogrel before PCI," the authors write.

"The significant reduction in adverse cardiovascular eventsbefore PCI suggests that a strategy of clopidogrel pretreatment shouldbe initiated as soon as possible. Accordingly, even if clopidogrel isnot given at presentation, once the decision is made to proceed withangiography, and hence possible PCI, initiation of pretreatment willmaximize the benefit," the researchers write.

###

(JAMA. 2005; 294:1224-1232. Available pre-embargo to the media at www.jamamedia.org.)

Editor's Note: The parent trial, CLARITY-TIMI 28, wassupported by the pharmaceutical partnership of Sanofi-Aventis andBristol-Myers Squibb. Dr. Sabatine is the recipient of a grant from theNational Heart, Lung, and Blood Institute. For financial disclosures ofthe authors, please see the JAMA article.



Story Source:

The above story is based on materials provided by JAMA and Archives Journals. Note: Materials may be edited for content and length.


Cite This Page:

JAMA and Archives Journals. "Medication Reduces Risk Of Heart Attack And Cardiovascular Death Before And After Angioplasty." ScienceDaily. ScienceDaily, 4 September 2005. <www.sciencedaily.com/releases/2005/09/050904122117.htm>.
JAMA and Archives Journals. (2005, September 4). Medication Reduces Risk Of Heart Attack And Cardiovascular Death Before And After Angioplasty. ScienceDaily. Retrieved September 3, 2014 from www.sciencedaily.com/releases/2005/09/050904122117.htm
JAMA and Archives Journals. "Medication Reduces Risk Of Heart Attack And Cardiovascular Death Before And After Angioplasty." ScienceDaily. www.sciencedaily.com/releases/2005/09/050904122117.htm (accessed September 3, 2014).

Share This



More Health & Medicine News

Wednesday, September 3, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Snack Attack: Study Says Action Movies Make You Snack More

Snack Attack: Study Says Action Movies Make You Snack More

Newsy (Sep. 2, 2014) You're more likely to gain weight while watching action flicks than you are watching other types of programming, says a new study published in JAMA. Video provided by Newsy
Powered by NewsLook.com
U.N. Says Ebola Travel Restrictions Will Cause Food Shortage

U.N. Says Ebola Travel Restrictions Will Cause Food Shortage

Newsy (Sep. 2, 2014) The U.N. says the problem is two-fold — quarantine zones and travel restrictions are limiting the movement of both people and food. Video provided by Newsy
Powered by NewsLook.com
Doctors Fear They're Losing Battle Against Ebola

Doctors Fear They're Losing Battle Against Ebola

AP (Sep. 2, 2014) As a third American missionary is confirmed to have contracted Ebola in Liberia, doctors on the ground in West Africa fear they're losing the battle against the outbreak. (Sept. 2) Video provided by AP
Powered by NewsLook.com
Tech Giants Bet on 3D Headsets for Gaming, Healthcare

Tech Giants Bet on 3D Headsets for Gaming, Healthcare

AFP (Sep. 2, 2014) When Facebook acquired the virtual reality hardware developer Oculus VR in March for $2 billion, CEO Mark Zuckerberg hailed the firm's technology as "a new communication platform." Duration: 02:24 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins